

The Role of Propylthiouracil in the Management of Graves' Disease in Adults

April 18, 2009

MEETING AGENDA

- 8:00 am – 8:30 am **Continental Breakfast**
- 8:30 am – 8:45 am **Introductions and Welcome**
Kenneth Burman, MD, ATA President, Washington Hospital Center
Mary Parks, MD, FDA
Donald Mattison, MD, NICHD, NIH; Anne Zajicek, MD, NICHD, NIH
David S. Cooper, MD, Meeting Chair, Johns Hopkins University
- 8:45 am – 9:30 am **Antithyroid Drugs: Pharmacology, Clinical Use and Adverse Events in Adults**
David S. Cooper, MD, Johns Hopkins University
- 9:30 am – 10:00 am **Management of Thyrotoxicosis in Pregnancy**
Susan Mandel, MD, MPH, University of Pennsylvania
- 10:00 am – 10:30 am **Antithyroid Drugs: Approval History and Labeling**
Naomi Lowy, MD, FDA
- 10:30 am – 10:45 am **Break**
- 10:45 am – 11:15 am **Frequency of PTU and Methimazole Use: Outpatient Prescription Utilization Data**
Laura Governale, PharmD, MBA, FDA
- 11:15 am – 11:45 am **PTU and Methimazole: Severe Liver Injury**
Joslyn Swann, PharmD, FDA
- 11:45 am – 12:00 pm **Discussion**
- 12:00 pm – 1:00 pm **Lunch**
- 1:00 pm – 1:45 pm **Methimazole Embryopathy and Possible Mechanisms of Teratogenesis**
Miyun Tsai-Turton, PhD, FDA
- 1:45 pm – 2:30 pm **Drug-Induced Liver Failure: Mechanisms**
John Senior, MD, FDA
- 2:15 pm – 2:45 pm **Break**
- 2:45 pm – 3:00 pm **Drug-Induced Liver Failure: Epidemiology and Role of Monitoring**
Mark Avigan, MD, FDA
- 3:00 pm – 3:30 pm **Discussion**
- 3:30 pm **Adjournment**